NCT05389514
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: KRAS, HLA+
Breast Cancer Tissue: 
Recruitment Status: Available

Drug Category: Chemotherapy, Immunotherapy, Therapeutic Antibody

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: Patient must have cancer that expresses the KRAS G12V mutation & appropriate HLA class II match (HLA-DRB1*07:01)
Exclusions: 
https://ClinicalTrials.gov/show/NCT05389514